Login Register Cart 0
General Review Article

异寡糖原蛋白（ISL）及其制剂：潜在的抗肿瘤药物

卷 26, 期 37, 2019

页: [6786 - 6796] 页: 11

弟呕挨: 10.2174/0929867325666181112091700

价格: $65

摘要

异寡糖原蛋白（2''，4''，4-三羟基查尔酮，ISL）是最重要的查尔酮化合物之一，主要来源于甘草根和许多其他植物。它具有强大的生物和药理活性，例如抗氧化，抗肿瘤，抗衰老，抗炎，抗糖尿病等作用。众多研究团队证明，ISL具有在多种癌细胞中进行抗生长和增殖的能力。体外和体内。同时，ISL抑制癌细胞增殖的潜在机制尚未得到很好的探索。然而，不良的生物利用度和低水溶性限制了其临床应用。这篇综述旨在全面综述ISL的药理学抗肿瘤活性及其在不同恶性肿瘤（尤其是乳腺癌细胞系）中的作用机制，并总结过去20年中用于克服其递送特性与临床应用之间的障碍的制剂开发。

关键词: 异黄体生成素，抗肿瘤，乳腺癌，机制，信号传导途径，制剂。

« Previous Next »
[1]
Peng, F.; Du, Q.; Peng, C.; Wang, N.; Tang, H.; Xie, X.; Shen, J.; Chen, J.A. Review: The pharmacology of isoliquiritigenin. Phytother. Res., 2015, 29(7), 969-977.
[http://dx.doi.org/10.1002/ptr.5348] [PMID: 25907962]
[2]
Kwon, H.M.; Choi, Y.J.; Choi, J.S.; Kang, S.W.; Bae, J.Y.; Kang, I.J.; Jun, J.G.; Lee, S.S.; Lim, S.S.; Kang, Y.H. Blockade of cytokine-induced endothelial cell adhesion molecule expression by licorice isoliquiritigenin through NF-kappaB signal disruption. Exp. Biol. Med. (Maywood), 2007, 232(2), 235-245.
[PMID: 17259331]
[3]
Chen, Y.P.; Zhang, Z.Y.; Li, Y.P.; Li, D.; Huang, S.L.; Gu, L.Q.; Xu, J.; Huang, Z.S. Syntheses and evaluation of novel isoliquiritigenin derivatives as potential dual inhibitors for amyloid-beta aggregation and 5-lipoxygenase. Eur. J. Med. Chem., 2013, 66, 22-31.
[http://dx.doi.org/10.1016/j.ejmech.2013.05.015] [PMID: 23786711]
[4]
Gaur, R.; Thakur, J.P.; Yadav, D.K.; Kapkoti, D.S.; Verma, R.K.; Gupta, N.; Khan, F.; Saikia, D. Bhakuni, R.S.; Erratum to: Synthesis, antitubercular activity, and molecular modeling studies of analogues of isoliquiritigenin and liquiritigenin, bioactive components from Glycyrrhiza glabra. Med. Chem. Res., 2015, 24, 3772-3774.
[http://dx.doi.org/10.1007/s00044-015-1420-y]
[5]
Iwata, S.; Nagata, N.; Omae, A.; Yamaguchi, S.; Okada, Y.; Shibata, S.; Okuyama, T. Inhibitory effect of chalcone derivatives on recombinant human aldose reductase. Biol. Pharm. Bull., 1999, 22(3), 323-325.
[http://dx.doi.org/10.1248/bpb.22.323] [PMID: 10220294]
[6]
Aponte, J.C.; Verástegui, M.; Málaga, E.; Zimic, M.; Quiliano, M.; Vaisberg, A.J.; Gilman, R.H.; Hammond, G.B. Synthesis, cytotoxicity, and anti-Trypanosoma cruzi activity of new chalcones. J. Med. Chem., 2008, 51(19), 6230-6234.
[http://dx.doi.org/10.1021/jm800812k] [PMID: 18798609]
[7]
Gaur, R.; Yadav, K.S.; Verma, R.K.; Yadav, N.P.; Bhakuni, R.S. In vivo anti-diabetic activity of derivatives of isoliquiritigenin and liquiritigenin. Phytomedicine, 2014, 21(4), 415-422.
[http://dx.doi.org/10.1016/j.phymed.2013.10.015] [PMID: 24262065]
[8]
Feldman, M.; Santos, J.; Grenier, D. Comparative evaluation of two structurally related flavonoids, isoliquiritigenin and liquiritigenin, for their oral infection therapeutic potential. J. Nat. Prod., 2011, 74(9), 1862-1867.
[http://dx.doi.org/10.1021/np200174h] [PMID: 21866899]
[9]
Wang, Z.; Wang, N.; Han, S.; Wang, D.; Mo, S.; Yu, L.; Huang, H.; Tsui, K.; Shen, J.; Chen, J. Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway. PLoS One, 2013, 8(7)e68566
[http://dx.doi.org/10.1371/journal.pone.0068566] [PMID: 23861918]
[10]
Lau, G.T.; Ye, L.; Leung, L.K. The licorice flavonoid isoliquiritigenin suppresses phorbol ester-induced cyclooxygenase-2 expression in the non-tumorigenic MCF-10A breast cell line. Planta Med., 2010, 76(8), 780-785.
[http://dx.doi.org/10.1055/s-0029-1240699] [PMID: 20033868]
[11]
Lorusso, V.; Marech, I. Novel plant-derived target drugs: a step forward from licorice? Expert Opin. Ther. Targets, 2013, 17(4), 333-335.
[http://dx.doi.org/10.1517/14728222.2013.773312] [PMID: 23425066]
[12]
Jang, D.S.; Park, E.J.; Hawthorne, M.E.; Vigo, J.S.; Graham, J.G.; Cabieses, F.; Santarsiero, B.D.; Mesecar, A.D.; Fong, H.H.; Mehta, R.G.; Pezzuto, J.M.; Kinghorn, A.D. Potential cancer chemopreventive constituents of the seeds of Dipteryx odorata (tonka bean). J. Nat. Prod., 2003, 66(5), 583-587.
[http://dx.doi.org/10.1021/np020522n] [PMID: 12762787]
[13]
Li, Y.; Zhao, H.; Wang, Y.; Zheng, H.; Yu, W.; Chai, H.; Zhang, J.; Falck, J.R.; Guo, A.M.; Yue, J.; Peng, R.; Yang, J. Isoliquiritigenin induces growth inhibition and apoptosis through downregulating arachidonic acid metabolic network and the deactivation of PI3K/Akt in human breast cancer. Toxicol. Appl. Pharmacol., 2013, 272(1), 37-48.
[http://dx.doi.org/10.1016/j.taap.2013.05.031] [PMID: 23747687]
[14]
Lee, S.H.; Kim, J.Y.; Seo, G.S.; Kim, Y.C.; Sohn, D.H. Isoliquiritigenin, from Dalbergia odorifera, up-regulates anti-inflammatory heme oxygenase-1 expression in RAW264.7 macrophages. Inflamm. Res., 2009, 58(5), 257-262.
[http://dx.doi.org/10.1007/s00011-008-8183-6] [PMID: 19169644]
[15]
Maggiolini, M.; Statti, G.; Vivacqua, A.; Gabriele, S.; Rago, V.; Loizzo, M.; Menichini, F.; Amdò, S. Estrogenic and antiproliferative activities of isoliquiritigenin in MCF7 breast cancer cells. J. Steroid Biochem. Mol. Biol., 2002, 82(4-5), 315-322.
[http://dx.doi.org/10.1016/S0960-0760(02)00230-3] [PMID: 12589938]
[16]
Kim, D.C.; Ramachandran, S.; Baek, S.H.; Kwon, S.H.; Kwon, K.Y.; Cha, S.D.; Bae, I.; Cho, C.H. Induction of growth inhibition and apoptosis in human uterine leiomyoma cells by isoliquiritigenin. Reprod. Sci., 2008, 15(6), 552-558.
[http://dx.doi.org/10.1177/1933719107312681] [PMID: 18487228]
[17]
Lin, L.C.; Wu, C.H.; Shieh, T.M.; Chen, H.Y.; Huang, T.C.; Hsia, S.M. The licorice dietary component isoliquiritigenin chemosensitizes human uterine sarcoma cells to doxorubicin and inhibits cell growth by inducing apoptosis and autophagy via inhibition of m-TOR signaling. J. Funct. Foods, 2017, 33, 332-344.
[http://dx.doi.org/10.1016/j.jff.2017.03.061]
[18]
Wu, C.H.; Chen, H.Y.; Wang, C.W.; Shieh, T.M.; Huang, T.C.; Lin, L.C.; Wang, K.L.; Hsia, S.M. Isoliquiritigenin induces apoptosis and autophagy and inhibits endometrial cancer growth in mice. Oncotarget, 2016, 7(45), 73432-73447.
[http://dx.doi.org/10.18632/oncotarget.12369] [PMID: 27708238]
[19]
YUAN, Xuan.; ZHANG, WANG.; Zhen, Liang.; Liang, ZHENG.; Sheng, WANG. Involvement of the mitochondrion-dependent and the endoplasmic reticulum stress-signaling pathways in isoliquiritigenin-induced apoptosis of HeLa cell. Biomed. Environ. Sci., 2013, 26, 268-276.
[http://dx.doi.org/10.3967/0895-3988.2013.04.005] [PMID: 23534467]
[20]
Hirchaud, F.; Hermetet, F.; Ablise, M.; Fauconnet, S.; Vuitton, D.A.; Prétet, J.L.; Mougin, C. Isoliquiritigenin induces caspase-dependent apoptosis via downregulation of HPV16 E6 expression in cervical cancer Ca Ski cells. Planta Med., 2013, 79(17), 1628-1635.
[http://dx.doi.org/10.1055/s-0033-1350956] [PMID: 24214831]
[21]
Mahalingam, S.; Gao, L.; Eisner, J.; Helferich, W.; Flaws, J.A. Effects of isoliquiritigenin on ovarian antral follicle growth and steroidogenesis. Reprod. Toxicol., 2016, 66, 107-114.
[http://dx.doi.org/10.1016/j.reprotox.2016.10.004] [PMID: 27773742]
[22]
Chen, H.Y.; Huang, T.C.; Shieh, T.M.; Wu, C.H.; Lin, L.C.; Hsia, S.M. Isoliquiritigenin induces autophagy and inhibits ovarian cancer cell growth. Int. J. Mol. Sci., 2017, 18, 2025.
[http://dx.doi.org/10.3390/ijms18102025]
[23]
Jung, J.I.; Lim, S.S.; Choi, H.J.; Cho, H.J.; Shin, H.K.; Kim, E.J.; Chung, W.Y.; Park, K.K.; Park, J.H. Isoliquiritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells. J. Nutr. Biochem., 2006, 17(10), 689-696.
[http://dx.doi.org/10.1016/j.jnutbio.2005.11.006] [PMID: 16517140]
[24]
Kanazawa, M.; Satomi, Y.; Mizutani, Y.; Ukimura, O.; Kawauchi, A.; Sakai, T.; Baba, M.; Okuyama, T.; Nishino, H.; Miki, T. Isoliquiritigenin inhibits the growth of prostate cancer. Eur. Urol., 2003, 43(5), 580-586.
[http://dx.doi.org/10.1016/S0302-2838(03)00090-3] [PMID: 12706007]
[25]
Yim, D.; Singh, R.P.; Agarwal, C.; Lee, S.; Chi, H. Agarwal, R.; A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells. Urol. Oncol-Semin Ori., 2005, 23, 379-380.
[26]
Lee, Y.M.; Lim, D.Y.; Choi, H.J.; Jung, J.I.; Chung, W.Y.; Park, J.H.Y. Induction of cell cycle arrest in prostate cancer cells by the dietary compound isoliquiritigenin. J. Med. Food, 2009, 12(1), 8-14.
[http://dx.doi.org/10.1089/jmf.2008.0039] [PMID: 19298190]
[27]
Zhang, B.; Lai, Y.; Li, Y.; Shu, N.; Wang, Z.; Wang, Y.; Li, Y.; Chen, Z. Antineoplastic activity of isoliquiritigenin, a chalcone compound, in androgen-independent human prostate cancer cells linked to G2/M cell cycle arrest and cell apoptosis. Eur. J. Pharmacol., 2018, 821, 57-67.
[http://dx.doi.org/10.1016/j.ejphar.2017.12.053] [PMID: 29277717]
[28]
Hu, F.W.; Yu, C.C.; Hsieh, P.L.; Liao, Y.W.; Lu, M.Y.; Chu, P.M. Targeting oral cancer stemness and chemoresistance by isoliquiritigenin-mediated GRP78 regulation. Oncotarget, 2017, 8(55), 93912-93923.
[http://dx.doi.org/10.18632/oncotarget.21338] [PMID: 29212198]
[29]
Hou, C.; Li, W.; Li, Z.; Gao, J.; Chen, Z.; Zhao, X.; Yang, Y.; Zhang, X.; Song, Y. Synthetic isoliquiritigenin inhibits human tongue squamous carcinoma cells through its antioxidant mechanism. Oxid. Med. Cell. Longev., 2017, 20171379430
[http://dx.doi.org/10.1155/2017/1379430] [PMID: 28203317]
[30]
Takahashi, T.; Takasuka, N.; Iigo, M.; Baba, M.; Nishino, H.; Tsuda, H.; Okuyama, T. Isoliquiritigenin, a flavonoid from licorice, reduces prostaglandin E2 and nitric oxide, causes apoptosis, and suppresses aberrant Crypt foci development. Cancer Sci., 2004, 95(5), 448-453.
[http://dx.doi.org/10.1111/j.1349-7006.2004.tb03230.x] [PMID: 15132774]
[31]
Yoshida, T.; Horinaka, M.; Takara, M.; Tsuchihashi, M.; Mukai, N.; Wakada, M.; Sakai, T. Combination of isoliquiritigenin and tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in colon cancer HT29 cells. Environ. Health Prev. Med., 2008, 13(5), 281-287.
[http://dx.doi.org/10.1007/s12199-008-0041-1] [PMID: 19568915]
[32]
Huang, Y.L.; Wei, F.; Zhao, K.; Zhang, Y.; Wang, D.; Li, X.H. Isoliquiritigenin inhibits colorectal cancer cells HCT-116 growth by suppressing the PI3K/AKT pathway. Open Life Sci., 2017, 12, 300-307.
[http://dx.doi.org/10.1515/biol-2017-0035]
[33]
Wang, Y.; Zheng, Q.; Pharmacy, S.O. University, S.; Study on isoliquiritigenin induced apoptosis of mouse melanoma B16F0 Cells. J; Shihezi Univ., 2016, p. 02.
[34]
Chen, X.; Yang, M.; Hao, W.; Han, J.; Ma, J.; Wang, C.; Sun, S.; Zheng, Q. Differentiation-inducing and anti-proliferative activities of isoliquiritigenin and all-trans-retinoic acid on B16F0 melanoma cells: Mechanisms profiling by RNA-seq. Gene, 2016, 592(1), 86-98.
[http://dx.doi.org/10.1016/j.gene.2016.07.052] [PMID: 27461947]
[35]
Wang, Y.; Ma, J.; Yan, X.; Chen, X.; Si, L.; Liu, Y.; Han, J.; Hao, W.; Zheng, Q. Isoliquiritigenin inhibits proliferation and induces apoptosis via alleviating hypoxia and reducing glycolysis in melanoma B16F10 cells; Recent Pat. Anticancer Drug Discov, 2016, p. 11.
[36]
Ma, J.; Fu, N.Y.; Pang, D.B.; Wu, W.Y.; Xu, A.L. Apoptosis induced by isoliquiritigenin in human gastric cancer MGC-803 cells. Planta Med., 2001, 67(8), 754-757.
[http://dx.doi.org/10.1055/s-2001-18361] [PMID: 11731922]
[37]
Hsu, Y.L.; Kuo, P.L.; Chiang, L.C.; Lin, C.C. Isoliquiritigenin inhibits the proliferation and induces the apoptosis of human non-small cell lung cancer A549 cells. Clin. Exp. Pharmacol. Physiol., 2004, 31, 414-418.
[http://dx.doi.org/10.1111/j.1440-1681.2004.04016.x] [PMID: 15236626]
[38]
Kayagaki, N.; Kawasaki, A.; Ebata, T.; Ohmoto, H.; Ikeda, S.; Inoue, S.; Yoshino, K.; Okumura, K.; Yagita, H. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med., 1995, 182(6), 1777-1783.
[http://dx.doi.org/10.1084/jem.182.6.1777] [PMID: 7500022]
[39]
Cuendet, M.; Oteham, C.P.; Moon, R.C.; Pezzuto, J.M. Quinone reductase induction as a biomarker for cancer chemoprevention. J. Nat. Prod., 2006, 69(3), 460-463.
[http://dx.doi.org/10.1021/np050362q] [PMID: 16562858]
[40]
Hsu, Y.L.; Kuo, P.L.; Lin, L.T.; Lin, C.C. Isoliquiritigenin inhibits cell proliferation and induces apoptosis in human hepatoma cells. Planta Med., 2005, 71(2), 130-134.
[http://dx.doi.org/10.1055/s-2005-837779] [PMID: 15729620]
[41]
Li, Z.X.; Li, J.; Li, Y.; You, K.; Xu, H.; Wang, J. Novel insights into the apoptosis mechanism of DNA topoisomerase I inhibitor isoliquiritigenin on HCC tumor cell. Biochem. Biophys. Res. Commun., 2015, 464(2), 548-553.
[http://dx.doi.org/10.1016/j.bbrc.2015.07.003] [PMID: 26159926]
[42]
Chen, G.; Hu, X.; Zhang, W.; Xu, N.; Wang, F.Q.; Jia, J.; Zhang, W.F.; Sun, Z.J.; Zhao, Y.F. Mammalian target of rapamycin regulates isoliquiritigenin-induced autophagic and apoptotic cell death in adenoid cystic carcinoma cells. Apoptosis, 2012, 17(1), 90-101.
[http://dx.doi.org/10.1007/s10495-011-0658-1] [PMID: 21956714]
[43]
Zhou, G.S.; Song, L.J.; Yang, B. Isoliquiritigenin inhibits proliferation and induces apoptosis of U87 human glioma cells in vitro. Mol. Med. Rep., 2013, 7(2), 531-536.
[http://dx.doi.org/10.3892/mmr.2012.1218] [PMID: 23229626]
[44]
Chen, H.; Zhang, B.; Yuan, X.; Yao, Y.; Zhao, H.; Sun, X.; Zheng, Q. Isoliquiritigenin-induced effects on Nrf2 mediated antioxidant defence in the HL-60 cell monocytic differentiation. Cell Biol. Int., 2013, 37(11), 1215-1224.
[http://dx.doi.org/10.1002/cbin.10156] [PMID: 23881796]
[45]
Chen, X.; Wu, Y.; Jiang, Y.; Zhou, Y.; Wang, Y.; Yao, Y.; Yi, C.; Gou, L.; Yang, J. Isoliquiritigenin inhibits the growth of multiple myeloma via blocking IL-6 signaling. J. Mol. Med. (Berl.), 2012, 90(11), 1311-1319.
[http://dx.doi.org/10.1007/s00109-012-0910-3] [PMID: 22648519]
[46]
Wang, Z.; Liu, J.; Zhang, Y.; Li, D. Isoliquiritigen Down-Regulating the Expression of the Matrix Metalloproteinases-2 in Human Fibrosarcoma HT1080 Cell, 2008, 215-219.
[47]
Si, L.; Yang, X.; Yan, X.; Wang, Y.; Zheng, Q. Isoliquiritigenin induces apoptosis of human bladder cancer T24 cells via a cyclin-dependent kinase-independent mechanism. Oncol. Lett., 2017, 14(1), 241-249.
[http://dx.doi.org/10.3892/ol.2017.6159] [PMID: 28693160]
[48]
Hengartner, M.O. Hengartner MOThe biochemistry of apoptosis. Nature 407: 770-776. Nature, 2000, 407, 770-776.
[http://dx.doi.org/10.1038/35037710] [PMID: 11048727]
[49]
Flores, E.R. Commentary on “Apoptosis, p53, and Tumor Cell Sensitivity to Anticancer Agents”. Cancer Res., 2016, 76(23), 6763-6764.
[http://dx.doi.org/10.1158/0008-5472.CAN-16-2997] [PMID: 27909063]
[50]
Wang, N.; Wang, Z.; Peng, C.; You, J.; Shen, J.; Han, S.; Chen, J. Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via β-catenin/ABCG2 signaling. Carcinogenesis, 2014, 35(11), 2544-2554.
[http://dx.doi.org/10.1093/carcin/bgu187] [PMID: 25194164]
[51]
Tang, H.; Peng, F.; Huang, X.; Xie, X.; Chen, B.; Shen, J.; Gao, F.; You, J.; Xie, X.; Chen, J. Neoisoliquiritigenin inhibits tumor progression by targeting GRP78-β-catenin signaling in breast cancer. Curr. Cancer Drug Targets, 2018, 18(4), 390-399.
[http://dx.doi.org/10.2174/1568009617666170914155355] [PMID: 28914191]
[52]
Lee, S.K.; Park, K.K.; Kim, K.R.; Kim, H.J.; Chung, W.Y. Isoliquiritigenin inhibits metastatic breast cancer cell-induced receptor activator of nuclear factor kappa-B ligand/osteoprotegerin ratio in human osteoblastic cells. J. Cancer Prev., 2015, 20(4), 281-286.
[http://dx.doi.org/10.15430/JCP.2015.20.4.281] [PMID: 26734591]
[53]
Hsia, S.M.; Shieh, T.M. Shih, Y.H.; Abstract 1991: Effects of isoliquiritigenin (ISL) on VEGF secretion in human breast cancer cell line MDA-MB-231. Cancer Res., 2014, 72, 1991-1991.
[54]
Subramaniam, D.; Ramalingam, S.; Houchen, C.W.; Anant, S. Cancer stem cells: a novel paradigm for cancer prevention and treatment. Mini Rev. Med. Chem., 2010, 10(5), 359-371.
[http://dx.doi.org/10.2174/138955710791330954] [PMID: 20370703]
[55]
Wang, N.; Wang, Z.; Wang, Y.; Xie, X.; Shen, J.; Peng, C.; You, J.; Peng, F.; Tang, H.; Guan, X.; Chen, J. Dietary compound isoliquiritigenin prevents mammary carcinogenesis by inhibiting breast cancer stem cells through WIF1 demethylation. Oncotarget, 2015, 6(12), 9854-9876.
[http://dx.doi.org/10.18632/oncotarget.3396] [PMID: 25918249]
[56]
Peng, F.; Tang, H.; Liu, P.; Shen, J.; Guan, X.; Xie, X.; Gao, J.; Xiong, L.; Jia, L.; Chen, J.; Peng, C. Isoliquiritigenin modulates miR-374a/PTEN/Akt axis to suppress breast cancer tumorigenesis and metastasis. Sci. Rep., 2017, 7(1), 9022.
[http://dx.doi.org/10.1038/s41598-017-08422-y] [PMID: 28827662]
[57]
Zimmers, T.A.; Fishel, M.L.; Bonetto, A. STAT3 in the systemic inflammation of cancer cachexia. Semin. Cell Dev. Biol., 2016, 54, 28-41.
[http://dx.doi.org/10.1016/j.semcdb.2016.02.009] [PMID: 26860754]
[58]
Ning, S.; Ma, X.; Zhu, D.; Shen, Z.; Liu, J.; Liu, Y.; Chen, J. Li, Z. Isoliquiritigenin attenuates MiR-21 expression via induction of PIAS3 in breast cancer cells. RSC Advances, 2017, 7, 18085-18092.
[http://dx.doi.org/10.1039/C6RA25511F]
[59]
Byrne, J.D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev., 2008, 60(15), 1615-1626.
[http://dx.doi.org/10.1016/j.addr.2008.08.005] [PMID: 18840489]
[60]
Liu, Y.; Lu, W. Recent advances in brain tumor-targeted nano-drug delivery systems. Expert Opin. Drug Deliv., 2012, 9(6), 671-686.
[http://dx.doi.org/10.1517/17425247.2012.682726] [PMID: 22607535]
[61]
Choi, C.H.J.; Alabi, C.A.; Webster, P.; Davis, M.E. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc. Natl. Acad. Sci. USA, 2010, 107(3), 1235-1240.
[http://dx.doi.org/10.1073/pnas.0914140107] [PMID: 20080552]
[62]
Ashley, C.E.; Carnes, E.C.; Phillips, G.K.; Padilla, D.; Durfee, P.N.; Brown, P.A.; Hanna, T.N.; Liu, J.; Phillips, B.; Carter, M.B. Targeted delivery of multicomponent cargos to cancer via protocell-like nanoporous particle-supported lipid bilayers. Nat. Mater., 2011, 10, 389-397.
[http://dx.doi.org/10.1038/nmat2992] [PMID: 21499315]
[63]
Florence, A.T. “Targeting” nanoparticles: the constraints of physical laws and physical barriers. J. Control. Release, 2012, 164(2), 115-124.
[http://dx.doi.org/10.1016/j.jconrel.2012.03.022] [PMID: 22484196]
[64]
Agarwal, S.; Sane, R.; Oberoi, R.; Ohlfest, J.R.; Elmquist, W.F. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev. Mol. Med., 2011, 13 e17
[http://dx.doi.org/10.1017/S1462399411001888] [PMID: 21676290]
[65]
Fei, G.; Zhang, J.; Fu, C.; Xie, X.; Fu, P.; You, J.; Tang, H.; Wang, Z.; Peng, L. Chen, J. iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability. INT. J. Nanomed., 2017, 12, 4147-4162.
[http://dx.doi.org/10.2147/IJN.S134148]
[66]
Zhang, X.; Qiao, H.; Zhang, T.; Shi, Y.; Ni, J. Enhancement of gastrointestinal absorption of isoliquiritigenin by nanostructured lipid carrier. Adv. Powder Technol., 2014, 25, 1060-1068.
[http://dx.doi.org/10.1016/j.apt.2014.02.012]
[67]
Zhang, X.Y.; Qiao, H.; Ni, J.M.; Shi, Y.B.; Qiang, Y. Preparation of isoliquiritigenin-loaded nanostructured lipid carrier and the in vivo evaluation in tumor-bearing mice. Eur. J. Pharm. Sci., 2013, 49(3), 411-422.
[http://dx.doi.org/10.1016/j.ejps.2013.04.020] [PMID: 23624327]
[68]
Noh, G.Y.; Ji, Y.S.; Park, S.N. Ceramide-based nanostructured lipid carriers for transdermal delivery of isoliquiritigenin: Development, physicochemical characterization, and in vitro skin permeation studies. Korean J. Chem. Eng., 2016, 1-7.
[69]
De Bartolo, L.; Morelli, S.; Gallo, M.C.; Campana, C.; Statti, G.; Rende, M.; Salerno, S.; Drioli, E. Effect of isoliquiritigenin on viability and differentiated functions of human hepatocytes maintained on PEEK-WC-polyurethane membranes. Biomaterials, 2005, 26(33), 6625-6634.
[http://dx.doi.org/10.1016/j.biomaterials.2005.04.021] [PMID: 15927248]
[70]
Yuan, Y.; Xing, J.G.; Wang, X.C.; Huang, C.S.; Xiao-Li, M.A.; Wen, Z.P. Enhanced absorption of isoliquiritigenin microemulsion in small intestine of rats. Chung Kuo Yao Hsueh Tsa Chih, 2013, 48, 128-131.
[71]
Boyapelly, K.; Bonin, M.A.; Traboulsi, H.; Cloutier, A.; Phaneuf, S.C.; Fortin, D.; Cantin, A.M.; Richter, M.V.; Marsault, E. Synthesis and Characterization of a Phosphate Prodrug of Isoliquiritigenin. J. Nat. Prod., 2017, 80(4), 879-886.
[http://dx.doi.org/10.1021/acs.jnatprod.6b00600] [PMID: 28252963]

Rights & Permissions Print Cite
Article Metrics
104
12
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy